Cerevel Therapeutics Holdings, Inc. CERE

Set alert

Price alert · CERE

All alert types
44.96 +44.96 —

Day range unavailable

52-week range unavailable

Open
—
Prev close
0.00
Mkt cap
8.19B
Vol
0
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
—
High
—
Forward P/E
-15.40
Beta
1.41
Short ratio
2.37
Inst. own
85.12%
Dividend
0.00
Ex-div date
Earnings
Aug 7, 2024
50-d avg
41.63
200-d avg
39.55
1y target
43.40

MAX chart

Chart tools
Interval

Events in this range
  • May 3, 2023Earnings: —; estimate -0.67; surprise —%
  • May 22, 2023Rating: Goldman Sachs · Neutral → Neutral
  • Aug 2, 2023Earnings: —; estimate -0.65; surprise —%
  • Aug 2, 2023Rating: Morgan Stanley · Overweight → Overweight
  • Aug 2, 2023Downgrade: B of A Securities · Buy → Neutral
  • Aug 2, 2023Rating: HC Wainwright & Co. · Buy → Buy
  • Aug 6, 2023Rating: Mizuho · Neutral → Neutral
  • Sep 27, 2023Rating: Piper Sandler · — → Overweight
  • Nov 1, 2023Earnings: —; estimate -0.63; surprise —%
  • Feb 27, 2024Earnings: —; estimate 0; surprise —%
  • May 8, 2024Earnings: —; estimate -0.61; surprise —%
  • Aug 7, 2024Earnings: —; estimate -0.58; surprise —%
Signals (48)
NameDateAgo
RSI: OverboughtAug 1, 20242 years ago
SMA: BullishJul 15, 20242 years ago
SMA: BullishJul 15, 20242 years ago
SMA: BearishJul 1, 20242 years ago
SMA: BearishMay 17, 20242 years ago
RSI: OverboughtMay 3, 20242 years ago
SMA: BullishApr 19, 20242 years ago
SMA: BearishApr 12, 20242 years ago
SMA: BullishMar 14, 20242 years ago
MACD: Sell SignalMar 14, 20242 years ago
RSI: OverboughtMar 14, 20242 years ago
SMA: BearishFeb 22, 20242 years ago
SMA: BullishDec 7, 20232 years ago
RSI: OverboughtDec 7, 20232 years ago
MACD: Buy SignalNov 8, 20232 years ago
SMA: BullishOct 10, 20233 years ago
SMA: BearishAug 8, 20233 years ago
SMA: BullishJul 25, 20233 years ago
MACD: Sell SignalJul 18, 20233 years ago
SMA: BearishJul 11, 20233 years ago

Newest 20 of 48.

Analyst view

Consensus: hold

Hold
Price target (mean) 43.40 -3.5% downside
Target (low)
31.00
Target (mean)
43.40
Target (high)
45.00

Recommendation trend

  • 1 month ago 9
  • 2 months ago 9
  • 3 months ago 6

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

CERE analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.80-0.80 – -0.80-0.63-27.0%00.0%1
Next quarter-0.73-0.73 – -0.73-0.61-19.7%00.0%1
Current year-2.83-3.25 – -2.41-2.67-6.0%00.0%2
Next year-2.92-3.30 – -2.54-2.83-3.2%00.0%2

Upgrades and downgrades

The latest rating changes

CERE analyst upgrades and downgrades
DateFirmActionFromTo
Sep 27, 2023Piper SandlerInitiated—Overweight
Aug 6, 2023MizuhoMaintainedNeutralNeutral
Aug 2, 2023Morgan StanleyMaintainedOverweightOverweight
Aug 2, 2023B of A SecuritiesDowngradeBuyNeutral
Aug 2, 2023HC Wainwright & Co.MaintainedBuyBuy
May 22, 2023Goldman SachsMaintainedNeutralNeutral
May 7, 2023MizuhoMaintained—Neutral
May 3, 2023Wells FargoUpgradeEqual-WeightOverweight
Apr 9, 2023TD CowenInitiated—Outperform
Apr 2, 2023HC Wainwright & Co.Reiterated—Buy
Mar 16, 2023JP MorganDowngradeOverweightNeutral
Mar 8, 2023MizuhoMaintained—Neutral
Feb 22, 2023Morgan StanleyMaintained—Overweight
Feb 22, 2023HC Wainwright & Co.Maintained—Buy
Feb 22, 2023Wells FargoDowngradeOverweightEqual-Weight
Feb 21, 2023Goldman SachsMaintainedNeutralNeutral
Dec 5, 2022JP MorganMaintained—Overweight
Nov 9, 2022MizuhoMaintained—Neutral
Nov 8, 2022HC Wainwright & Co.Maintained—Buy
Oct 31, 2022Loop CapitalInitiated—Buy
Oct 19, 2022B of A SecuritiesInitiated—Buy
Sep 28, 2022Cantor FitzgeraldInitiated—Overweight
Sep 25, 2022Wells FargoInitiated—Overweight
Sep 20, 2022Goldman SachsMaintained—Neutral
Sep 12, 2022Evercore ISI GroupInitiated—Outperform
Aug 22, 2022MizuhoMaintained—Neutral
Aug 21, 2022Morgan StanleyMaintained—Overweight
Aug 8, 2022StifelMaintained—Buy
Aug 2, 2022MizuhoMaintained—Neutral
Jul 6, 2022MizuhoInitiated—Neutral